

# Wei Hu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2075579/publications.pdf>

Version: 2024-02-01

39  
papers

1,281  
citations

361413

20  
h-index

361022

35  
g-index

40  
all docs

40  
docs citations

40  
times ranked

2784  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 803.	2.5	5
2	Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. <i>Gynecologic Oncology</i> , 2021, 160, 777-785.	1.4	21
3	Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. <i>Gynecologic Oncology</i> , 2021, 161, 104-112.	1.4	4
4	MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. <i>Gynecologic Oncology</i> , 2021, 163, 181-190.	1.4	5
5	CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. <i>Cell Reports</i> , 2021, 36, 109549.	6.4	20
6	Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3545-3555.	2.5	5
7	Clinical and biological significance of EZH2 expression in endometrial cancer. <i>Cancer Biology and Therapy</i> , 2020, 21, 147-156.	3.4	21
8	Pan-cancer clinical and molecular analysis of racial disparities. <i>Cancer</i> , 2020, 126, 800-807.	4.1	25
9	Sustained Adrenergic Activation of YAP1 Induces Anoikis Resistance in Cervical Cancer Cells. <i>IScience</i> , 2020, 23, 101289.	4.1	9
10	Analysis of Heavy Metal Contamination of Agricultural Soils and Related Effect on Population Health—A Case Study for East River Basin in China. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1996.	2.6	10
11	Transient receptor potential vanilloid 4 channels as therapeutic targets in diabetes and diabetes-related complications. <i>Journal of Diabetes Investigation</i> , 2020, 11, 757-769.	2.4	10
12	Arsenic concentrations, diversity and co-occurrence patterns of bacterial and fungal communities in the feces of mice under sub-chronic arsenic exposure through food. <i>Environment International</i> , 2020, 138, 105600.	10.0	41
13	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-14.	2.3	24
14	Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. <i>Oncotarget</i> , 2020, 11, 2819-2833.	1.8	4
15	Association between Single-nucleotide Polymorphisms of RXRG and Genetic Susceptibility to Type 2 Diabetes in South China. <i>Current Molecular Medicine</i> , 2020, 20, 408-414.	1.3	3
16	Building a circular RNA centered gene regulation network associated with cervical squamous cell carcinoma. <i>Epigenomics</i> , 2020, 12, 1883-1898.	2.1	0
17	Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. <i>Gynecologic Oncology</i> , 2019, 154, 524-530.	1.4	24
18	GnRH-R Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 969-979.	4.1	12

#	ARTICLE	IF	CITATIONS
19	Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. <i>Scientific Reports</i> , 2019, 9, 17589.	3.3	12
20	<i>PRKRA</i> /PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 162-172.	4.1	23
21	Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. <i>Cancer Research</i> , 2018, 78, 3233-3242.	0.9	69
22	Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 464-473.	4.1	4
23	The role of tumor microenvironment in resistance to anti-angiogenic therapy. <i>F1000Research</i> , 2018, 7, 326.	1.6	47
24	FABP4 as a key determinant of metastatic potential of ovarian cancer. <i>Nature Communications</i> , 2018, 9, 2923.	12.8	151
25	ADH1B promotes mesothelial clearance and ovarian cancer infiltration. <i>Oncotarget</i> , 2018, 9, 25115-25126.	1.8	24
26	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. <i>Nature Communications</i> , 2017, 8, 310.	12.8	169
27	Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 41-46.	1.4	17
28	Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. <i>Cell Reports</i> , 2017, 21, 2785-2795.	6.4	32
29	Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. <i>Oncotarget</i> , 2017, 8, 96496-96505.	1.8	49
30	Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1344-1352.	4.1	41
31	Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2894-2904.	4.1	37
32	Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1713-1724.	7.0	69
33	XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. <i>Clinical Cancer Research</i> , 2015, 21, 3286-3297.	7.0	37
34	<i>PTEN</i> Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1466-1475.	4.1	20
35	Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 448-459.	7.0	48
36	Molecular Biomarkers of Residual Disease after Surgical Debulking of High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3280-3288.	7.0	80

#	ARTICLE	IF	CITATIONS
37	Biologic Effects of Platelet-Derived Growth Factor Receptor $\hat{\pm}$ Blockade in Uterine Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2740-2750.	7.0	14
38	Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 1061-1067.	3.4	34
39	Notch3 Pathway Alterations in Ovarian Cancer. <i>Cancer Research</i> , 2014, 74, 3282-3293.	0.9	59